Abstract：【Objective】To explore the expression of p53 in triple-negative breast cancer and its relationship with prognosis. 【Methods】A total of 79 patients with operable triple-negative breast cancer treated in our hospital were selected. Fresh cancer tissues and adjacent tissues were collected during operation, and p53 expression was detected by immunohistochemistry. The patients were followed up to observe the recurrence, metastasis and overall survival (OS). The relationship of p53 expression with recurrence, metastasis and OS was analyzed. 【Results】The positive expression rate of p53 (40.51%) in triple-negative breast cancer was higher than that in adjacent tissues (11.39%), and the difference was statistically significant(P<0.05).The proportion of N3 and grade Ⅲ in p53 high expression group was higher than that in p53 low expression group (both P<0.05). The follow-up time was 36-60 (49.6 ± 4.9) months. A total of 70 patients were followed up and 9 were lost to follow-up. A total of 17 patients relapsed. Of which, the recurrence rate in the p53 high expression group was significantly higher than that in the p53 low expression group, and the difference was statistically significant(P<0.05). A total of 11 patients had metastasis. The metastasis rate in the p53 high expression group (32.14%) was significantly higher than that in the p53 low expression group, and the difference was statistically significant(P<0.05). During the follow-up period, 17 patients died. Kaplan-Meier method and Log-rank test results showed that patients with triple-negative breast cancer plus high expression of p53 had shorter OS than those patients with triple-negative breast cancer plus low expression of p53 (P<0.05). Multivariate COX results showed that tumor size (T), lymph node stage (N), p53 expression, and histological grade were independent prognostic factors affecting the death of triple-negative breast cancer patients (P<0.05). 【Conclusion】The p53 expression is up-regulated in triple negative breast cancer, and patients with high p53 expression have a poor prognosis and high risk of recurrence, metastasis, and death.
杨喜佳, 刘琪. 三阴性乳腺癌组织中p53表达对患者预后的影响[J]. 医学临床研究, 2021, 38(9): 1324-1327.
YANG Xi-jia, LIU Qi. Effect of p53 Expression on Prognosis in Triple Negative Breast Cancer. JOURNAL OF CLINICAL RESEARCH, 2021, 38(9): 1324-1327.
[1] 吴春晓,顾凯,王春芳,等.上海市女性乳腺癌流行现况、回顾与比较分析[J].外科理论与实践,2019,24(5):421-427.
[2] 陈莉娜.三阴性乳腺癌概述[J].徐州医科大学学报,2019,39(6):470-472.
[3] KAUR RP, VASUDEVA K, KUMAR R, et al. Role of p53 gene in breast cancer:focus on mutation spectrum and therapeutic strategies[J].Curr Pharm Des,2018, 24(30): 3566-3575.
[4] 易清清,杨荣,梁冬雨,等.P53表达与乳腺癌患者复发转移及预后的关系[J].检验医学,2019,34(12):1107-1110.
[5] GOLMOHAMMADI R, PEJHAN A. The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients[J].J Pak Med Assoc,2012, 62(9): 871-875.
[6] SCHON K, TISCHKOWITZ M. Clinical implications of germline mutations in breast cancer:TP53[J].Breast Cancer Res Treat,2018, 167(2): 417-423.
[7] YOSHIHIRO Y, KANAI M, KOU T, et al. Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing[J].J Hum Genet,2020, 65(2): 125-132.
[8] 韩洁洁,韩丽丽,杨伟伟,等.三阴性乳腺癌组织中P53、Ki67、CK5/6表达分析[J].山东医药,2019,59(20):72-74.
[9] 袁明明,任晓燕,陶玉梅,等.P53在浸润性乳腺癌中的表达及意义[J].天津医药,2019,47(2):167-170.
[10] 先洁.覃雪,曹友德.Numb在三阴乳腺癌中抑制HDM2泛素化降解p53[J].中国生物工程杂志,2019,39(7):1-7.
2021, Vol. 38 
